


Thursday - Saturday September 9-11, 2004; World Conference-Program

Thursday	September 9, 2004	
02:00 PM	Session 1: The basis of antiinfective treatment	
	02:00 PM	Pharmacokinetics and tissue penetration of antiinfectives O. Cars, Uppsala, Sweden
	02:20 PM	Extra vs. intracellular penetration of antiinfectives P. Tulkens, Louvain, Belgium
	02:40 PM	Microdialysis studies in healthy volunteers and patients M. Müller, Vienna, Austria
	03:00 PM	In vitro and in vivo models of infection W.A. Craig, Madison, USA
	03:20 PM	Summary and discussion by chairmen
03:30 PM	Coffee Break	
	Sponsors' boo Paul-Ehrlich-E Ehrlich dye lab	xhibition
04:00 PM	Session 2: Principles of dosing and methods of individualization	
	04:00 PM	Why sex and age are unimportant – a pharmacokinetic perspective N. Holford, Auckland, New Zealand
	04:20 PM	Drug monitoring to optimize therapy R. Jelliffe, Los Angeles, USA
	04:40 PM	PK/PD Optimization of antiinfectives by adaptive feedback control A. Forrest, Buffalo, USA
	05:00 PM	Population PK and Monte Carlo Simulation G.L. Drusano, Albany, USA
	05:20 PM	Summary and discussion by chairmen
05:30 PM	End of presentations on Thursday	
06:00 PM	Opening Ceremony at the Althoff - Frerich Hall	
07:45 PM	Reception at the Ehrlich Plaza	



Friday	September 1	0, 2004	
07:00 AM	Registration		
	Sponsors' booths Paul-Ehrlich-Exhibition Ehrlich dye laboratory		
08:00 AM	Session 3: Antiinfectives' drug development and regulatory processes		
	08:00 AM	Guidelines of FDA and EMEA for clinical studies H. Kemmler, Bern, Switzerland	
	08:20 AM	Predicting drug interactions L.Z. Benet, San Francisco, USA	
	08:40 AM	Adverse events and antiinfectives' drug interactions – lessons of the last 20 years R. Stahlmann, Berlin, Germany	
	09:00 AM	Summary and discussion by chairmen	
09:10 AM	Coffee break		
	Sponsors' booths Paul-Ehrlich-Exhibition Ehrlich dye laboratory		
09:30 AM	Session 4: Antifungals and antivirals		
	09:30 AM	Antifungals A. Louie, Albany, USA	
	09:55 AM	Antivirals	

G.L. Drusano, Albany, USA

Summary and discussion by chairmen

10:20 AM



Friday	September 1	0, 2004
02:05 PM	Session 5: Special populations and clinical pharmacodynamics	
	02:05 PM	Dosing issues in neonates and children J.N. v. d. Anker, Washington, USA
	02:25 PM	Dosing of antiinfectives in special populations H. Derendorf, Gainesville, USA
	02:45 PM	Dosing guidelines in patients with renal replacement F. Thalhammer, Vienna, Austria
	03:05 PM	Summary and discussion by chairmen
03:20 PM	Session 6: Treatment of infection according to site of infection	
	03:20 PM	Dosing of antibiotics in skin and soft tissue infections W. Graninger, Vienna, Austria
	03:40 PM	Dosing of antibiotics in urinary tract infections K.G. Naber, Straubing, Germany
	04:00 PM	Dosing of antibiotics in respiratory tract infections H. Lode, Berlin, Germany
	04:25 PM	Sepsis and other difficult conditions T. Welte, Hannover, Germany
	04:45 PM	Summary and discussion by chairmen
05:00 PM	End of presentations on Friday	
07:00 PM	Ceremonial Gala Evening to celebrate Paul Ehrlich's 150 th Birthday (ends 11:30 PM)	

Saturday September 11, 2004

07:00 AM Registration

Sponsors' booths Paul-Ehrlich-Exhibition Ehrlich dye laboratory

08:30 AM Session 7: Dosing of antiinfectives


08:30 AM	Hepatitis C – dosing regimens S. Rossol, Rüsselsheim, Germany
08:50 AM	Anti-tuberculosis treatment R.S. Wallis, Newark, USA
09:10 AM	Preventing antimalarial resistance N. White, Bangkok, Thailand
09:30 AM	Treatment and dosing of <i>Helicobacter pylori</i> infection – when pharmacology meets clinic P. Malfertheiner, Magdeburg, Germany
09:50 AM	Summary and discussion by chairmen

10:00 AM Coffee break

Paul-Ehrlich-Exhibition Colors and art – artists use Ehrlich's colors Ehrlich dye laboratory

10:15 AM Session 8: Views in PK/PD and controversies

10:15 AM	Vancomycin – Clinical pharmacodynamics in hospitalized patients J.J. Schentag, Buffalo, USA
10:35 AM	Protein binding – a microbiologist's view B. Wiedemann, Bonn, Germany
10:50 AM	Protein binding – a pharmacologist's view H. Derendorf, Gainesville, Florida
11:05 AM	Can resistance be prevented? P.C. Appelbaum, Hershey, USA
11:25 AM	Can resistance be prevented? / Intermittent vs continuous infusion – ISAP position J.W. Mouton, Nijmegen, Netherlands
11:50 AM	Effectiveness of antiinfectives: do not forget the patient! J.C. Pechère, Geneva, Switzerland
12:05 PM	Summary and discussion by chairmen



Saturday	September 11, 2004	
01:30 PM	"Magic Bullets" – Tools and perspectives	
	01:30 PM	Pharmacokinetics and pharmacodynamics – concepts in drug development from Ehrlich to modern PK/PD L.Z. Benet, San Francisco, USA
	02:00 PM	The role of animal experimentation in designing antiinfective therapy from Ehrlich to today's methods W.A. Craig, Madison, USA
	02:30 PM	The challenges of advancing Paul Ehrlich's chemotherapeutic principles in the present era R.C. Moellering, Boston, USA
	03:00 PM	Ehrlich's modern dream – therapeutic antibodies B. Groner, Frankfurt/M, Germany
03:30 PM	End of WCDA: Closing remarks	

K.G. Naber, Straubing, Germany